Rasmus Holm-Jorgensen is an accomplished finance and strategy executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as the Chief Financial Officer at AAVantgarde Bio, Rasmus has a diverse background that includes pivotal roles at Acrivon Therapeutics, Kiniksa Pharmaceuticals, and Synageva BioPharma. Rasmus played a crucial role in preparing Acrivon for its NASDAQ IPO and subsequent financing activities. Prior experience encompasses leadership positions at GN Group and Novo Nordisk, where Rasmus managed large-scale operations across several countries and successfully led financial transformations. Rasmus holds a Master's degree in Economics from the University of Copenhagen and has completed executive education programs at esteemed institutions such as Harvard Business School and Stanford University.
This person is not in any teams
This person is not in any offices